2021
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 78: 1635-1654. PMID: 34649702, PMCID: PMC8504484, DOI: 10.1016/j.jacc.2021.08.021.Peer-Reviewed Original ResearchConceptsLipid-modulating agentsEndothelial activationLow high-density lipoprotein cholesterolCOVID-19High-density lipoprotein cholesterolLipid modulating agentsHigh triglyceride levelsMultiorgan manifestationsStatin trialsLipoprotein cholesterolSystemic inflammationTriglyceride levelsJACC StateWorse outcomesInflammatory responsePatient managementRCTsCoronavirus diseaseViral entrySystematic searchLipid raft disruptionTrialsPatientsRaft disruptionPrevention
2016
Niacin
Krumholz HM. Niacin. Circulation Cardiovascular Quality And Outcomes 2016, 9: 343-344. PMID: 27407051, DOI: 10.1161/circoutcomes.116.003094.Peer-Reviewed Original Research
2014
Role of Nicotinic Acid in Atherosclerosis Prevention—Reply
Jackevicius CA, Krumholz HM. Role of Nicotinic Acid in Atherosclerosis Prevention—Reply. JAMA Internal Medicine 2014, 174: 649-649. PMID: 24711201, DOI: 10.1001/jamainternmed.2013.12811.Peer-Reviewed Original Research
2013
Use of Niacin in the United States and Canada
Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of Niacin in the United States and Canada. JAMA Internal Medicine 2013, 173: 1379-1381. PMID: 23753308, DOI: 10.1001/jamainternmed.2013.6489.Peer-Reviewed Original Research